without splenomegaly and absence of lymphadenopathies, for which they have also been referred to as non-nodal MCL (6) (7) (8) (9) (10) (11) (12) (13) . In the last years, we and others have proposed that some of these asymptomatic cases may represent a preneoplastic condition that could lead to the development of MCL or instead correspond to other types of lymphoproliferative disorders with the t(11;14)(q13;q32) (8, (13) (14) (15) .
In an attempt to gain further insight into the heterogeneous behavior of MCL, we have compared a series of classical MCL cases requiring chemotherapy with a homogeneous group of asymptomatic individuals harboring a monoclonal expansion of cyclin D1-positive mature B-cells in the peripheral blood (PB), that carry the t(11;14)(q13;q32), in the absence of splenomegaly or nodal enlargement due to this
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Author Manuscript Published OnlineFirst on December 18, 2013; DOI: 10.1158/1078-0432.CCR- process. These cases will be hereafter referred to as MALD1 (monoclonal asymptomatic lymphocytosis, cyclin D1-positive), with the intention of not to prejudge the neoplastic nature of the process. Of note, these asymptomatic cases has ever required or received any treatment after a minimum follow-up of 26 months (median, 71 months). In this study, we have sought for biological differences between MALD1 and classical MCL, investigating molecular pathways that could be enriched in each of these groups. Finally, we selected differentially expressed genes whose protein products could be easily analyzed by flow cytometry, to develop a useful tool for distinguishing MALD1 from classical MCL in routine clinical practice.
Research. 
Materials and Methods

Patients and samples
Thirty patients studied between 1994 and 2012 who fulfilled the WHO diagnostic criteria for MCL and had available cryopreserved PB samples were included in this study (1) . From them, 17 were diagnosed with MCL requiring chemotherapy at diagnosis, and 13 corresponded to individuals with monoclonal expansion of mature B-cells in PB carrying the t(11;14)(q13;q32) and displaying cyclin D1 overexpression (MALD1).
Aggressive variants with blastoid or pleomorphic features were excluded from the MCL group. Criteria for inclusion in the MALD1 group were as follows: lack of symptoms, no enlargement of lymphoid organs related to the process (by physical examination or by imaging studies), and follow-up > 2 years without requiring any treatment along the whole follow-up period. The decision not to treat was based on a number of features including lack of constitutional symptoms, absence of progressive or bulky disease and no severe cytopenia or impaired end-organ function as a consequence of the process. In this setting, a watchful waiting approach was adopted. Eight healthy individuals with similar age and gender distribution were also included as controls for microarray analyses. This study was approved by the Institutional Review Board of the participating institutions, where required, and was conducted in accordance with the Declaration of Helsinki.
Histological, immunohistochemical and immunocytochemical studies
Histological and immunohistochemical analyses were performed on formalin-fixed, paraffin-embedded (FFPE) samples. Immunocytochemical studies were carried out on air-dried formalin-acetone fixed PB smears. Cyclin D1 expression was assessed on histological sections and/or PB smears of all cases with t(11;14), regardless of CD5 expression. In each case, two primary antibodies were used: clone P2D11F11
Research. (Novocastra, NewCastle, UK) and clone SP4 (Neomarkers Inc, Fremont, CA, USA). The immunohistochemical analysis of SOX11 was performed with an anti-SOX11 polyclonal antibody (Atlas Antibodies, Stockholm, Sweden), as previously described (9) . SOX11 immunostaining on decalcified tissues is not sensitive enough so it was not performed in BM biopsies. The percentage of Ki-67 positive cells (clone MIB-1, Dako, Glostrup, Denmark) was recorded for all available cases.
Morphologic and immunophenotypic analysis of B-lymphocytes
PB and bone marrow (BM) smears were stained with May-Grünwald-Giemsa.
CD38 and CD200 expression was analyzed in PB by flow cytometry using a mouse IgG1 anti-human CD38 moAb (HB7, BD Biosciences, San Jose, CA, USA) and a mouse IgG1 anti-human CD200 moAb (MRCOX-104, BD Biosciences). The expression of both markers was assessed with respect to the mean fluorescence intensity observed in cells labelled with a matched isotypic monoclonal antibody. Lymphocytes were gated in the forward and side scatter plot to avoid the inclusion of debris, monocytes, and doublets.
Regarding CD200 expression analysis, and in order to ensure the exclusion of possible contaminating T and natural killer cells, the resultant cells were then gated to select CD2+ cells, which were electronically excluded (invert gate).
G-banding cytogenetics and fluorescence in situ hybridization (FISH)
Chromosome analyses were carried out on lymphoid cells from PB and BM 72-hour TPA-stimulated cultures following standard procedures (16) . When karyotypes presented with three or more cytogenetic aberrations, these were classified as complex.
FISH analysis was performed on PB and BM using the IGH/CCND1 dual color dual fusion translocation probe and ATM and TP53 locus specific probes (Abbott Molecular, Abbott
Research. Park, IL, USA). Cut-offs were 1%, 10% and 10%, respectively. FISH for IGH/CCND1 was also performed on FFPE samples (cut-off 15%) (17) .
Analysis of the major translocation cluster (MTC) breakpoint region of IGH/CCND1
and cyclin D1 mRNA isoforms Analysis of the MTC breakpoint region of IGH/CCND1 was performed following the BIOMED-2 protocol (18) . Positive cases were sequenced by capillary electrophoresis.
Sequences were aligned to previously reported MTC region sequences using ClustalW.
Identification of the IGHJ segments involved in the translocation and alignment to previously reported sequences were performed using the IgBlast public server. CCND1 mRNA isoforms were assessed as previously described (19) .
Mutational studies of immunoglobulin heavy chain V (IGHV) genes
The mutational status of IGHV genes was assessed as previously described (20) . Samples in which < 2% of base pairs differed from those of the consensus sequence were considered unmutated.
Microarray analyses
Microarray analyses were performed on RNA isolated from B-lymphocytes obtained from PB by means of immunomagnetic bead selection (B-cell isolation kit II, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) that yielded purities of ≥90% as assessed by flow cytometry (CD19 APC, clone SJ25C1, BD Biosciences). In cases carrying the t(11;14)(q13;q32) translocation, the percentage of pathologic cells as assessed by flow cytometry was ≥ 80% of total B-lymphocytes.
Microarray expression profiles were obtained using the Affymetrix Human Exon logarithmic transcript-level using the robust multi-chip average (RMA) (21) and core annotations, obtaining a total of 18,708 transcript clusters. Normalized data were then filtered to avoid noise created by non-expressed transcript clusters. This filtering was performed in two steps: first, only transcripts with intensity signal > 10% of the mean of all intensities of the studied groups were selected; then, those with a variance > 80% were considered for further analysis, which lead to 3,479 transcript clusters. Linear Models for Microarray (LIMMA) (22) , a moderated Student's T-test, was used for detecting differentially expressed genes between groups. Correction for multiple comparisons was performed using false discovery rate (FDR) and only genes with an adjusted P < 0.05 were considered significant. Hierarchical cluster analysis was also performed to see how samples and genes aggregated. All data analysis was performed in R (version 2.15.0) with bioconductor (23) and aroma.affymetrix packages (version 2.7.0) (24). Functional analysis was performed using the Ingenuity Pathway Analysis (IPA) (version 8.5) (25) and Gene Set Enrichment Analysis (GSEA) computational method (26) . The gene sets with P < 0.05 and FDR < 0.2 were considered to be enriched and potentially relevant. The functional heat map was generated by aggregating results of the GSEA and IPA pathway analyses into common categories. The mean of gene expression values belonging to each pathway was taken as the representative value for each sample. Microarray raw data have been deposited in the Gene Expression Omnibus (GEO) database with series accession number GSE45717 (27) .
Gene expression analysis by quantitative RT-PCR (qRT-PCR)
cDNAs were prepared from 1 µg RNA using the High-Capacity cDNA Archive Kit 
(Hs00178587_m1) and ADAMS28 (Hs00248020_m1) along with beta-glucuronidase (GUSB; part number 4326320E) using specific commercially available TaqMan ® gene expression assays. Relative expression levels were calculated with the 2 -ΔΔCt method using GUSB as endogenous control.
Generation of the CD38/CD200 classifier
The Classification and Regression Trees strategy (CART) was used to generate a classification algorithm based on CD38 and CD200 expression assessed by flow cytometry. This algorithm was built using R with the rpart package. Rpart is a non parametrical two-step method, which can be easily represented as a decision tree graph.
The first step finds the single variable that best splits the cases into two groups, on the basis of the minimum Gini Index, an estimation based on all possible splits using all available variables. All possible cut-off values for all variables considered in the model are tested to select the split that most decreases the Gini Index at the first node. The cases are then assigned to each newly generated node and this process is recursively applied to each of the descendant nodes, until no improvement can be achieved. In the second step, the resulting full tree is trimmed back using a cross-validation procedure (28) . The 95% confidence interval (CI) of the proportions of correctly classified patients by the proposed decision tree were computed using methods with continuity correction (29) .
Statistical Analyses
Comparisons were performed using the Mann-Whitney's U-test for continuous 
Results
Clinical presentation, laboratory findings and follow-up of MCL and MALD1 cases
The main clinical and laboratory features at diagnosis are detailed in Table 1 and   Supplementary Tables S1 and S2 . The reason for referral was different between the two groups: while most MCL patients presented with palpable lymphadenopathies (14/17), 12/13 MALD1 cases were referred because of abnormal routine PB tests, including lymphocytosis (7/13 cases) and atypical lymphocytes in PB smears with a normal lymphocyte count (5/13 cases). In the remaining case, referral was due to a single submandibular lymphadenopathy related to an inflammatory condition (sarcoid granulomatous reaction). In most MALD1 cases, the morphology of abnormal lymphocytes in blood smears was similar to that of typical chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL) without smudge cells, whereas in MCL cases the atypical lymphocytes displayed more irregular nuclear contours, as previously reported (30) . The absolute lymphocyte count at presentation ranged from 3.1 to 12.2 x10 9 /L in MALD1 cases and from 0.7 to 69 x10 9 /L in MCL patients. MALD1 lymphocyte counts over time have been plotted in Supplementary Fig. S1 . All MALD1 individuals and most MCL patients (69%) showed PB involvement by flow cytometry, with percentages of abnormal lymphocytes ranging from 11% to 76% in MALD1 cases and from 0% to 86% in MCL patients. There were no significant differences between MALD1 (5/13) and MCL (6/14) cases regarding CD23 expression, nor in the intensity of surface immunoglobulin expression. Interestingly, the moderate/high intensity of surface immunoglobulin expression in all MALD1 cases (13/13) was different to that reported in MBL with typical CLL phenotype, usually negative or weakly positive (31) . MCL cases showed lower hemoglobin level (P = 0.012), with higher erythrocyte sedimentation rates (ESR) and β 2 -microglobulin levels than MALD1 cases (P = 0.001 for 
MALD1 and MCL show distinct histological features
The main histological and immunohistochemical features of both groups are detailed in Table 1 and Supplementary Table S1 . In MCL patients, the involvement of 
MALD1 shares diagnostic cytogenetic and molecular features with MCL
The main cytogenetic and molecular features are detailed in Table 1 and   Supplementary Table S2 . All MALD1 and MCL cases displayed a t(11;14)(q13;q32) by G-banding cytogenetics and/or FISH. qRT-PCR analysis confirmed increased CCND1 mRNA expression levels in MALD1 and MCL samples when compared to healthy controls, and these higher levels correlated with cyclin D1 protein overexpression, as detected by IHC. In 0/12 MALD1 and 1/7 MCL cases, the truncated CCND1 mRNA isoform, associated to shorter survival, was identified (19) Table S3 ) (32) . Finally, all MALD1 cases analyzed showed clonal IGHVDJ gene rearrangements.
MALD1 cells are involved in immune reactions and show evidence of transit through the germinal center
As a part of the routine staging protocol for MCL, upper and lower endoscopy was performed in most cases (33) . A follicular chronic gastritis associated with Helicobacter pylori infection was detected in gastric mucosa biopsies from three MALD1 subjects.
Immunohistochemical analysis of these samples revealed numerous cyclin D1-positive lymphoid cells in the follicular mantles of the acquired MALT (Fig. 1A, 1B, 1C) . FISH analysis confirmed the presence of t(11;14)(q13;q32) in these cells, and molecular analysis showed the same IGH clonal rearrangements as those found in the other tissues studied (data not shown). Biopsies taken after routine antibiotic treatment for the gastric infection revealed a slight residual atrophy without evidence of bacilli and, more importantly, complete absence of lymphoid infiltrates (Fig. 1D, 1E, 1F ). In contrast, in a IGHV genes, whereas only 4/13 MCL patients had somatic mutations (P < 0.001) ( Table 1 and Supplementary Table S2 
probably occurred before their clonal expansion, an observation that contrasts with the pre-germinal center origin postulated for MCL (15, 34) .
Gene expression profile of clonal B-cells reveals significant biological differences between MALD1 and MCL
To better understand the basis for possible biological differences between MCL and MALD1, we analyzed the gene expression profiles of enriched B-cell fractions isolated from PB of five MALD1 subjects, five MCL patients and eight healthy individuals.
Unsupervised hierarchical clustering of gene expression data revealed robust differences between MALD1 and MCL B-cells ( Fig. 2A) . When compared to normal PB B-cells from healthy individuals, MALD1 and MCL clustered together, indicating that PB B-cells from both groups share significant differences with normal B-cells (Fig. 2B) . Supervised analysis between MALD1 and MCL samples identified a gene signature composed of 174 differentially expressed transcript clusters (171 genes). This signature clustered together MALD1 and normal B-cells (Fig. 2C, Supplementary Table S4 ). The microarray results were confirmed by qRT-PCR analysis of a subset of top differentially expressed genes ( Supplementary Fig. S2 ). Validation was performed in the same ten cases (5 MCL and 5 MALD1) used for microarray analyses. The 20 remaining cases (12 MCL and 8 MALD1) were used as a validation set.
The MALD1/MCL gene signature included CD38 (log Fold Change [logFC] =1.51; adj. P = 0.024), upregulated in MCL, and CD200 (logFC = 2.04; adj. P = 0.005), upregulated in MALD1, two flow cytometry markers commonly used in the study of peripheral blood lymphocytosis. Unlike previous reports (9, 37), SOX11 was not part of the MALD1/MCL gene signature, even though statistically significant differences in SOX11 mRNA expression between MALD1 and MCL were detected by qRT-PCR ( Supplementary Fig. S2 ). This apparent discordance can be explained by the differences between the probe sets included in the Human Exon 1.0 ST array (used in this study), and the 3'IVT array probe sets (HGU133 Plus2 arrays) used in those studies ( Supplementary   Fig. S3 ).
Pathway analysis using the Ingenuity Pathway Analysis tool indicated that the MALD1/MCL gene signature was significantly enriched in genes involved in two main biological processes, namely inflammatory responses in MALD1, and cell growth and proliferation in MCL (Fig. 3, Supplementary Table S5 ). These differences were confirmed and further refined using the GSEA tool. Many cancer-related signatures (cell cycle and proliferation, Myc deregulation and self-renewal), as well as gene signatures associated to cyclin D1/Cdk4 activation, were specifically enriched in MCL. In addition, we observed a significant enrichment for DNA-damage repair pathways (ATM and global genomic nucleotide excision repair pathways). Both cell cycle and DNA-damage repair related pathways have been previously invoked in the pathogenesis of MCL (28, 29) . In contrast, MALD1 gene expression profiles were highly enriched in gene sets related to inflammatory responses, B-cell activation, immunoregulatory interactions, cytokine signaling, and lymphocyte/cell adhesion and migration, suggesting that inflammatory cues drive the biology of these cells, as also supported by the histological data (Fig. 1) .
Thus, gene expression analysis identified significant differences in selected gene expression programs between MCL and MALD1 B-cells, in concordance with the clinical and histological evidence.
Surface CD38/CD200 expression by flow cytometry is useful to discriminate between MALD1 and MCL
Among other specific surface molecules found to be differentially expressed between MALD1 and MCL, we chose to further validate CD200 and CD38 on PB samples, given their widespread use in routine phenotypic panels for the study of lymphocytosis (30) . Particularly, CD38 was highly expressed in MCL patients but not in MALD1 cases, an observation further confirmed by qRT-PCR analysis (P = 0.007) (Fig.   4A ). Flow cytometry data on CD38 surface expression in PB were available in 37 cases (11/17 MCL and 13/13 MALD1 from the original series, and 13 additional MCL cases). In agreement with the molecular data, MCL patients displayed a significantly higher percentage of CD38+ B-cells (median 89%, range 0-100%) than that observed among MALD1 individuals (median 14%, range 0-35%) (P <0.001) (Fig. 4B and 4C and Supplementary Table S2 ).
Regarding CD200, it was highly expressed in MALD1 cases but not in MCL patients, and this observation was confirmed by qRT-PCR (P < 0.001) (Fig. 4D ). CD200 surface expression was available in PB B-cell lymphocytes of 27 cases (2/17 MCL and 12/13 MALD1 from the original series, and 13 additional MCL cases) ( Fig. 4E and 4F , Supplementary Table S2 ). In agreement with the qRT-PCR data, all MCL cases showed very low or absent CD200 expression (median 0%, range 0-5%), whereas the majority of MALD1 cases analyzed showed a higher percentage of CD200+ B-cells (median 24%, range 0-95%; P < 0.001). These observations suggest that flow cytometric analysis of CD38 and CD200 expression on clonal B-cells from PB samples is useful for the distinction between MCL (CD38+/CD200-) and MALD1 cases (CD38-/CD200+). Based on these findings, we designed a classifier to discriminate between both entities in the clinical setting. We generated a CART based on two splits, the first one, CD38 ≥ 40%, classifies patients as MCL, whereas the second split, CD200 ≥ 2%, assigns the MALD1 cases (Fig. 5A) . We have considered a third Non-Classified category, encompassing with available sample, SOX11 expression was also low and showed mutated IGHV genes. Interestingly, when analyzing the whole series, mutated IGHV cases showed statistically significant higher levels of SOX11 expression than unmutated cases (P = 0.001). These differences were maintained when considering only MCL patients (P = 0.027).
DISCUSSION
Based on current diagnostic criteria, MCL encompasses a spectrum of cases ranging from the usual, aggressive variants to rare, non-nodal cases that remain asymptomatic for many years, even without treatment (6) (7) (8) (9) (10) (11) (12) (13) 38) . This clinical heterogeneity probably reflects incomplete knowledge of the MCL pathogenesis, with the resulting diagnostic oversimplification. In fact, current prognostic indexes for MCL (IPI, MIPI) (39, 40) are not suitable for MALD1 cases, as they would label some of them as intermediate or even high-risk MCL, mainly due to the presence of leukocytosis and/or to advanced age, despite their benign clinical course (34) . It has been speculated that some of the asymptomatic cases represent a preneoplastic condition that would either lead to the development of MCL or remain stable lifelong (7-13, 15, 41, 42) . It is even possible that some asymptomatic cases could belong to a different biological category sharing only some of the diagnostic features of MCL (8, 13, 15) . Therefore, it is crucial to gain further insight into the molecular differences between MCL and MALD1 and to find biological markers that, in addition to clinical presentation, allow identifying MALD1 cases and avoid their overtreatment.
While previous series dealing with this topic are rather heterogeneous (7, 9, 10, 12, 13), we have attempted to characterize a homogeneous group of cases (MALD1) presenting without splenomegaly or nodal enlargement due to the disease, and never requiring treatment despite a long follow-up (median, 71 months). This group was compared with a cohort of classical MCL patients, from which aggressive histological variants had been excluded to avoid confounding factors related to disease progression. 
for malignant transformation (3, 46) . While the biological and clinical behavior of MALD1 is far from that expected in neoplastic cells, we have shown that MALD1 lymphocytes carry genetic abnormalities unseen in normal B-cells as t (11;14) , and clonal expansion.
This could eventually prime them for neoplastic transformation in the proper biological context. Given the exceptionality and limited knowledge of preneoplastic lesions in the lymphoid system, we cannot rule out that MALD1 may act in the long-term as a precursor of MCL, similar to what has been reported for MBL and CLL (31, (47) (48) (49) . In this regard, MALD1 cases would be related to the fraction (20-40%) of MCL cases with hypermutated IGHV genes, which typically show non-nodal disease at presentation, an indolent clinical course, and a long disease-free survival (35, 36) . Finally, according to our results, another possibility that cannot be excluded is that MALD1 cases might instead belong to a distinct disease category, biologically unrelated to MCL.
Several groups have addressed the need for reliable markers to identify cyclin D1-positive cases not requiring early treatment. Among them, SOX11, for which an oncogenic role has been recently proposed, has been the most widely explored (50, 51) .
Lack of SOX11 expression, alone or in combination with other genes, has been proposed as a candidate marker with conflicting results (9, 13, 52) . The limitation of these markers is that, as the majority of asymptomatic cases only show PB expression, the assessment must be made by qRT-PCR in isolated B-cells from PB. As these techniques are not readily implementable in all laboratories, one of the aims of our study was to identify differentially expressed genes between MALD1 and MCL, providing the basis for a simple routine diagnostic test. Among the differentially expressed and validated genes in our study, we selected CD38 and CD200 because antibodies for their proteins are already used in current diagnostic flow cytometry panels for mature B-cell lymphoproliferative processes (53).
Research. -13-1077 CD38 is an ectoenzyme with an unclear function in B cells (54) . CD38 expression is a well-recognized prognostic factor in CLL and it has also been suggested as a marker that partially differentiates nodal from non-nodal MCL (7). In our study, CD38 expression was found to be consistently high in MCL while low or absent in MALD1 cases. It has been proposed that CD38 may favor neoplastic B cell survival by engaging CD31, an adhesion molecule expressed by endothelial cells (55) . In MALD1 cases, low CD38 expression may minimize the interaction of MALD1 B cells with CD31-expressing microvessels, thus attenuating clonal B-cell accumulation.
CD200 is an Ig superfamily member frequently upregulated in CLL and has been proposed as a useful marker for the differential diagnosis between CLL and MCL (56, 57) . CD200 was found to be consistently low or absent in all MCL, but highly expressed in most MALD1 cases. CD200 binds to CD200R, an inhibitory receptor expressed by both lymphoid and myeloid cells. It is tempting to speculate that an increased frequency of inhibitory signals emerging from CD200-CD200R interaction attenuates the proliferation of MALD1 B cells, thus contributing to the asymptomatic behavior of MALD1 cases.
Conversely, reduced CD200 expression by conventional MCL may contribute to its more aggressive biological behavior.
Despite the low prevalence of MALD1 cases, we have generated an algorithm based on CD38 and CD200 expression that correctly assigned most MALD1 and MCL cases; more importantly, such algorithm did not classify any of these cases in the opposite category. SOX11 expression by qRT-PCR did not improve the classification obtained by the algorithm. Our results indicate that a combined analysis of CD38 and CD200 by flow cytometry could be used to discern between MALD1 and MCL. However, as some cases show close values to the cut-off of both markers, these parameters should be considered in the whole clinical and biological context. 
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